At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 12,979 enrolled
Drug / intervention
Moxidectin +2 moredrug
Likely dose
Moxidectin 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Treatment With Albendazole
In Brief
A Phase 3 clinical trial evaluating Moxidectin, Ivermectin, and 1 other intervention for Onchocerciasis. Completed, enrolled 12,979 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnchocerciasis
CountriesCôte d’Ivoire, Democratic Republic of the Congo
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartMay 2021
Primary CompletionSep 2024
TodayJul 2026
First PostedMar 17, 2020
Enrollment StartMay 3, 2021
Primary CompletionSep 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.3 years ago
Interventions
Moxidectindrug
2 mg tablets, encapsulated for blinding
Ivermectindrug
3 mg tablets, encapsulated for blinding
Albendazoledrug
400 mg tablets